Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Review, Bossone and Eagle discuss the epidemiology, management and outcomes of the most common aortic diseases: aortic aneurysms and acute aortic syndromes, including aortic dissection.
A new study identifies microRNAs that are enriched in exosomes secreted from cardiosphere-derived cells and which are associated with cardiac repair in pigs and humans with dilated cardiomyopathy.
In this Review, Entcheva and Kay discuss a decade of important developments and applications of optogenetics to the heart, focusing on near-term and longer-term clinical translation of this technology in cardiology.
In this Review, Mayr and colleagues describe the growing number of omic techniques, discuss their strengths and weaknesses, outline network theory, and highlight exemplars of novel approaches that combine gene regulatory and co-expression networks, proteomics, metabolomics, lipidomics and phenomics with informatics techniques to provide new insights into cardiovascular disease.
A new study identifies the mitochondrial protein ALDH4A1 as a potential biomarker of atherosclerosis and as a target antigen of protective autoantibody A12, which might have therapeutic potential.
In the AFFIRM-AHF trial, the use of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency was associated with a reduction in hospitalization for heart failure and cardiovascular death.
In patients with recurrent pericarditis, treatment with rilonacept, an engineered fusion protein that acts as an IL-1 trap, leads to a rapid resolution of recurrent pericarditis episodes and reduces the risk of pericarditis recurrence.
Omecamtiv mecarbil (a myosin activator) and mavacamten (a myosin inhibitor) have beneficial effects in patients with heart failure with reduced ejection fraction or obstructive hypertrophic cardiomyopathy, respectively.
Findings from two clinical trials indicate that cryoablation as first-line treatment is superior to drug therapy for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation.
In the TIPS-3 trial, a single polypill comprising blood-pressure-lowering and cholesterol-lowering drugs, together with a daily dose of aspirin, reduced cardiovascular events in people at risk of cardiovascular disease.
Sotagliflozin reduces the risk of adverse cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease or worsening heart failure according to the SCORED and SOLOIST-WHF trials.
In patients with heart failure who are carriers of a clonal haematopoiesis driver mutation in DNMT3A, circulating monocytes have a pro-inflammatory transcriptome, which might worsen disease progression.
In this Review, Padmanabhan and Dominiczak discuss how genomics has transformed our understanding of blood pressure regulation and hypertension, summarizing the current knowledge of blood pressure genomics and highlighting the opportunities and challenges for drug repurposing and pharmacogenomics for the treatment of hypertension.
This Review summarizes the latest evidence indicating that platelet and endothelial dysfunction are essential components of COVID-19 pathology, describes the potential mechanisms underlying the contribution of cardiovascular risk factors to the most severe outcomes in COVID-19, and highlights the roles of coagulopathy, thrombocytopathy and endotheliopathy in COVID-19 pathogenesis.